News

404

PRISM BioLab raised 100 million yen in Series C funding from Eisai

PRISM BioLab raised 100 million yen in Series C funding from Eisai

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics™”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve further growth through pre-clinical studies and R&D of the pipeline.

Read Full Press Release

Scroll to top
en_USEnglish